



March 28, 2023

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : Intimation regarding reappointment of Directors of HealthCare Global Enterprises Limited (“Company”).
Stock Code : BSE – 539787, NSE – HCG
Reference : Regulation 30 read with Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”).

Pursuant to Regulation 30 read with Schedule III Part A of the SEBI LODR Regulations, we hereby intimate that, based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company (“Board”) at their meeting held on Monday, March 27, 2023, has approved:

- (i) the reappointment of Dr. B. S. Ajaikumar (DIN: 00713779) as a Whole-time Director, designated as the Executive Chairman of the Company, effective from July 01, 2023, for a period up to June 30, 2025, or until the occurrence of the events set out under clause 14.6 of the Investment Agreement executed on June 04, 2020 between the Company, Dr. B. S. Ajaikumar, and Aceso Company Pte. Ltd (“Investment Agreement”) (corresponding to Article 14.6 of Part B of the Articles of Association of the Company), whichever is earlier, subject to the approval of the shareholders of the Company. The current term of office of Dr. B. S. Ajaikumar as Executive Chairman ends on June 30, 2023.
- (ii) the reappointment of Mrs. Anjali Ajaikumar Rossi (DIN: 08057112) as a Whole-time Director, designated as Executive Director of the Company, effective from April 01, 2023, for a period up to: (a) June 30, 2026, or (b) termination of the employment of the ‘Executive Chairman’ in accordance with clause 14.6 of the Investment Agreement (corresponding to Article 14.6 of Part B of the Articles of Association of the Company), whichever is earlier, subject to the approval of the shareholders of the Company. The current term of office of Mrs. Anjali Ajaikumar Rossi as Executive Director ends on March 31, 2023.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



The Company proposes to seek approval of the shareholders of the Company for the above matters by way of Postal Ballot.

The additional details as required under Regulation 30 of the SEBI LODR Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, with regard to the reappointment of Dr. B. S. Ajaikumar and Mrs. Anjali Ajaikumar Rossi, are enclosed as Annexure A and Annexure B.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer



Annexure A

Reappointment of Dr. B. S. Ajaikumar as Executive Chairman of the Company and Mrs. Anjali Ajaikumar Rossi as Executive Director of the Company

Sl. No.	Particulars required	Dr. B. S. Ajaikumar	Anjali Ajaikumar Rossi
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Dr. B. S. Ajaikumar has been reappointed as a Whole-time Director, designated as Executive Chairman of the Company, subject to the approval of the shareholders of the Company.	Anjali Ajaikumar Rossi has been reappointed as a Whole-time Director, designated as Executive Director of the Company, subject to the approval of the shareholders of the Company.
2.	Date of appointment/ cessation (as applicable) and term of appointment	The reappointment is effective from July 01, 2023, for a period up to June 30, 2025, or until the occurrence of the events set out under clause 14.6 of the Investment Agreement, (corresponding to Article 14.6 of Part B of the Articles of Association of the Company) whichever is earlier.	The reappointment is effective from April 01, 2023, for a period up to: (a) June 30, 2026, or (b) termination of the employment of the ‘Executive Chairman’ in accordance with clause 14.6 of the Investment Agreement (corresponding to Article 14.6 of Part B of the Articles of Association of the Company), whichever is earlier.
3.	Brief Profile (in case of appointment of Directors)	Provided in Annexure B.	Provided in Annexure B.
4.	Disclosure of relationships between Directors (in case of appointment of Directors)	Dr. B. S. Ajaikumar is the father of Anjali Ajaikumar, Executive Director of the Company.	Anjali Ajaikumar is the daughter of Dr. B. S. Ajaikumar, Executive Chairman of the Company.
5.	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/024 dated June 20, 2018 issued by the BSE and NSE, respectively.	Dr. B. S. Ajaikumar is not debarred from holding the office of Director pursuant to any SEBI order or any other such authority.	Anjali Ajaikumar is not debarred from holding the office of Director pursuant to any SEBI order or any other such authority.



Annexure B

Brief profile of Dr. B. S. Ajaikumar

Dr B. S. Ajaikumar is the Executive Chairman of HCG. Dr Ajaikumar founded HCG to realize his vision of making advanced cancer care accessible to all. He has been the driving force behind HCG's growth since its inception. He has served as the CEO of the Company from July 2006 to January 2021.

Dr Ajaikumar's contributions to the field of cancer care in India and his success as a first-generation physician entrepreneur have been widely recognized. He has been awarded the Ernst and Young Entrepreneur of the Year Award, the CII Regional Emerging Entrepreneurs Award, and the BC Roy Award by the Indian Science Monitor. Dr Ajaikumar is also the recipient of the Karnataka Rajyotsava Award.

Dr Ajaikumar has been a practicing oncologist in the US and India for over three decades. He completed his residency training in Radiotherapy from the MD Anderson Hospital and Tumour Institute of the University of Texas, and his residency training in Oncology from the University of Virginia Hospital, Charlottesville. He received his MBBS from St. Johns Medical College, Bangalore.

Brief profile of Mrs. Anjali Ajaikumar Rossi

Anjali Ajaikumar is a healthcare professional and committed social entrepreneur currently serving as an Executive Director at HealthCare Global Enterprises Ltd (HCG). In her fifteen years of experience as an administrator and strategist she has worked extensively to redefine the patient experience for cancer patients in India.

With her deep understanding of the expectations of patients and caregivers, Anjali has set up centralized divisions for quality assurance, clinical excellence, operations, nursing, and other functions to drive organizational efficiency, employee engagement, patient satisfaction, and continuous advancements in the quality of care across all 22 HCG centres in India and overseas.

Anjali is an MBA graduate in Entrepreneurship from Babson College and has valuable insights into project consulting and leadership from her past stints in the US. She is a mentor to start-ups within the healthcare space, and brings a unique perspective along with a wealth of experience to provide guidance and strategic support to emerging entrepreneurs.

She is committed to raising awareness about cancer issues, and has organized numerous fundraising programs to aid financially challenged patients. In her role with the non-profit International Human Development and Upliftment Academy, Anjali is active in promoting rural education, fostering women empowerment, and creating awareness about environmental issues.